PD-L1-Targeted Lutetium-177 Radiotherapy Shrinks Triple-Negative Breast Tumors in Mice

Researchers have reported encouraging preclinical results for a new targeted radiotherapy approach against triple-negative breast cancer, one of the hardest breast cancer subtypes to treat. The work, published on 26 October 2026 as open-access original research, tested whether delivering radiation directly to PD-L1-expressing tumor cells could slow tumor growth and extend survival in a mouse model of the disease.

The rationale for the approach rests on two biological features. PD-L1 is described by the authors as a biologically available and radiosensitive target in triple-negative breast cancer, yet targeted radiotherapy against it had been relatively unexplored. The team used athymic nude mice bearing human MDA-MB-231 tumors, a model chosen for its high PD-L1 expression. Animals were assigned to three groups: a saline control group and two treatment groups receiving either 9.25 MBq or 18.5 MBq of the radiolabeled antibody, designated [177Lu]Lu-atezolizumab. Single photon emission computed tomography imaging was acquired to track the agent, and organ dosimetry was quantified from biodistribution measurements taken at multiple time points after injection.

The therapeutic results were statistically significant in both treated groups. Tumor volumes were significantly reduced compared with controls by day 20 in the higher-dose group (18.5 MBq, p < 0.05) and by day 24 in the lower-dose group (9.25 MBq, p < 0.05). Median survival increased from 35 days in the control group to 52 days with the 9.25 MBq dose and 60 days with the 18.5 MBq dose, a difference the authors report as significant at p < 0.01. Tumor volumes and body weights were monitored for 60 days, and one- and two-way ANOVAs and log rank tests were used to assess differences between treatment groups.

Safety signals in this early-stage model were likewise favorable. Despite that hepatic dose, no weight loss was observed in the treated groups, and histological examination of relevant organs using H&E staining revealed only minimal toxicity in the clearance organs. The authors emphasize that these findings support [177Lu]Lu-atezolizumab as a novel targeted radiotherapy with the potential to improve immunotherapy outcomes in triple-negative breast cancer.

Several caveats frame the significance of the work. The study is preclinical: it was conducted in immunocompromised xenograft mice carrying a single human tumor cell line, so it cannot speak directly to efficacy or safety in patients, and the nude mouse model limits assessment of immune-mediated effects that atezolizumab would normally engage. The published version is an accepted-manuscript release, citable with a permanent DOI but subject to further edits before the final Version of Record appears. Within those limits, the combination of dose-dependent tumor control, extended median survival, and minimal observed organ toxicity provides a quantitative foundation for advancing PD-L1-targeted radiotherapy toward further preclinical and, eventually, translational evaluation.

Subject of Research: Preclinical evaluation of lutetium-177 labeled PD-L1-targeted radiotherapy for triple-negative breast cancer in a xenograft mouse model

Article Title: Preclinical evaluation of PD-L1 targeted radiotherapy in a xenograft mouse model of triple-negative breast cancer

Article References: Moye, J., Houson, H. A., Massicano, A. V. F., Gultekin, K., Sridhar, S., James, S., Warram, J. M., Lapi, S. E., & Sorace, A. G. (2026). Preclinical evaluation of PD-L1 targeted radiotherapy in a xenograft mouse model of triple-negative breast cancer. EJNMMI Research. https://doi.org/10.1186/s13550-026-01537-2

Image Credits: AI Generated

DOI: 10.1186/s13550-026-01537-2

Keywords: triple-negative breast cancer, PD-L1, atezolizumab, lutetium-177, targeted radiotherapy, radiopharmaceuticals, SPECT imaging, dosimetry, xenograft mouse model, preclinical study, MDA-MB-231, EJNMMI Research